Sector News

AstraZeneca makes CinCor Pharma acquisition

January 14, 2023
Life sciences

AstraZeneca (AZ) has agreed to acquire CinCor Pharma (CinCor) – a company which concentrates on developing novel treatments for hypertension and chronic kidney disease.

The addition of the company will increase AZ’s cardiorenal pipeline as it will include CinCor’s candidate drug, baxdrostat.

Baxdrostat is a selective, oral small molecule inhibitor of aldosterone synthase – the enzyme responsible for the synthesis of aldosterone in the adrenal gland – and can be used for blood pressure lowering in treatment-resistant hypertension.

The drug represents a potentially leading next-generation aldosterone synthase inhibitor as it is selective for aldosterone synthase and, critically, spares the cortisol pathway among humans.

There is also potential for combining baxdrostat with Farxiga – a move which upholds AZ’s strategy to provide benefits throughout cardiorenal diseases, especially where there is a high unmet medical need.

Marc de Garidel, chief executive officer of CinCor, reflected: “We are excited about the proposed acquisition of CinCor by AZ as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.”

He added: “CinCor is committed to ensuring a smooth transition of the development responsibilities to AZ a once the acquisition is consummated.”

Mene Pangalos, executive vice president BioPharmaceuticals R&D, AZ, concluded: “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat.

“Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”

by John Pinching

Source: pharmatimes.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach